Synonyms: SYN-115 | SYN115
Compound class:
Synthetic organic
Comment: An investigational orally available and selective adenosine A2A receptor antagonist.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Tozadenant (SYN115) is being evaluated in Phase 3 clinical trials for the treatment of Parkinson's disease (see NCT01283594 and NCT02453386). Phase 2b results are published in [2]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01283594 | Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off | Phase 2/Phase 3 Interventional | Biotie Therapies Inc. | ||
NCT02453386 | Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients | Phase 3 Interventional | Biotie Therapies Inc. |